| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot knockout validation; human; 1:1000; loading ...; fig 3e
| Pham Q, Taniyama D, Sekino Y, Akabane S, Babasaki T, Kobayashi G, et al. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma. BMC Cancer. 2021;21:737 pubmed publisher |
- western blot knockout validation; human; loading ...; fig 2d, 2h
| Brunner A, Suryo Rahmanto A, Johansson H, Franco M, Viiliäinen J, Gazi M, et al. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer. elife. 2020;9: pubmed publisher |
- western blot knockout validation; mouse; 1:1000; loading ...; fig 2b
| Mao N, Gao D, Hu W, Hieronymus H, Wang S, Lee Y, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18:1577-1586 pubmed publisher |
- western blot knockout validation; mouse; loading ...; fig 5a
| Anker J, Naseem A, Mok H, Schaeffer A, Abdulkadir S, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591 pubmed publisher |
- immunohistochemistry; human; loading ...; fig s6k
- western blot knockout validation; mouse; loading ...; fig 2a
| Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, et al. PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth. Nature. 2017;546:554-558 pubmed publisher |
- western blot; mouse; fig 1
- western blot knockout validation; human; fig 1
| Yuzugullu H, Von T, Thorpe L, Walker S, Roberts T, Frank D, et al. NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016;2:16030 pubmed publisher |
- immunohistochemistry knockout validation; rat; 1:50; fig 1
| Chen P, Qin L, Li G, Tellides G, Simons M. Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGF?)-dependent smooth muscle cell phenotype modulation. Sci Rep. 2016;6:33407 pubmed publisher |
- western blot knockout validation; mouse; loading ...; fig 5a
| Chen R, Duan J, Li L, Ma Q, Sun Q, Ma J, et al. mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 2017;36:979-988 pubmed publisher |
- immunohistochemistry knockout validation; rat; 1:50; fig 1
| Chen F, Rosiene J, Che A, Becker A, LoTurco J. Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. Development. 2015;142:3601-11 pubmed publisher |
- western blot knockout validation; mouse; loading ...; fig 9b
| Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, et al. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol. 2014;34:900-13 pubmed publisher |
- immunohistochemistry knockout validation; mouse; fig 3
| Rodriguez O, Lai E, Vissapragada S, Cromelin C, Avetian M, Salinas P, et al. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol. 2009;174:2051-60 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3c
| Lin G, Li J, Cai J, Zhang H, Xin Q, Wang N, et al. RNA-binding Protein MBNL2 regulates Cancer Cell Metastasis through MiR-182-MBNL2-AKT Pathway. J Cancer. 2021;12:6715-6726 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig s8a
| Correia de Sousa M, Calo N, Sobolewski C, Gjorgjieva M, Clement S, Maeder C, et al. Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers (Basel). 2021;13: pubmed publisher |
- western blot; human; fig 2g
| Ali A, Kuo W, Kuo C, Lo J, Chen M, Daddam J, et al. E3 ligase activity of Carboxyl terminus of Hsc70 interacting protein (CHIP) in Wharton's jelly derived mesenchymal stem cells improves their persistence under hyperglycemic stress and promotes the prophylactic effects against diabetic cardiac damages. Bioeng Transl Med. 2021;6:e10234 pubmed publisher |
- immunohistochemistry; mouse; 1:200; loading ...; fig 1g
- western blot; mouse; 1:1000; loading ...; fig 3b
| Langdon C, Gadek K, Garcia M, Evans M, Reed K, Bush M, et al. Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity. Nat Commun. 2021;12:5520 pubmed publisher |
- immunohistochemistry; mouse; loading ...; fig 5a
- western blot; mouse; loading ...; fig 5d
- western blot; human; fig 5d
| Hamm M, Sohier P, Petit V, Raymond J, Delmas V, Le Coz M, et al. BRN2 is a non-canonical melanoma tumor-suppressor. Nat Commun. 2021;12:3707 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3f
| Diaz González M, Buberman A, Morales M, Ferrer I, Knafo S. Aberrant Synaptic PTEN in Symptomatic Alzheimer's Patients May Link Synaptic Depression to Network Failure. Front Synaptic Neurosci. 2021;13:683290 pubmed publisher |
- immunohistochemistry; mouse; 1:1000; loading ...; fig 4
| Hewa Bostanthirige D, Komaragiri S, Joshi J, Alzahrani M, Saini I, Jain S, et al. The helix-loop-helix transcriptional regulator Id4 is required for terminal differentiation of luminal epithelial cells in the prostate. Oncoscience. 2021;8:14-30 pubmed publisher |
- western blot; human; loading ...; fig 3b
| Wang H, Radomska H, Phelps M, Iorns E, Tsui R, Denis A, et al. Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. elife. 2020;9: pubmed publisher |
- western blot; human; loading ...; fig 6a
| Tan Y, Sementino E, Liu Z, Cai K, Testa J. Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis. Sci Rep. 2020;10:15837 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3b
| Kerwin J, Khan I, Iorns E, Tsui R, Denis A, Perfito N, et al. Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. elife. 2020;9: pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig s1d
| Hermanova I, Z iga Garc a P, Caro Maldonado A, Fernandez Ruiz S, Salvador F, Mart n Mart n N, et al. Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. J Exp Med. 2020;217: pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 4
| Gugel I, Ebner F, Grimm F, Czemmel S, Paulsen F, Hagel C, et al. Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis. Cancers (Basel). 2020;12: pubmed publisher |
- western blot; human; fig 5a
| Veschi V, Mangiapane L, Nicotra A, Di Franco S, Scavo E, Apuzzo T, et al. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene. 2020;39:987-1003 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:500; loading ...; fig 1c
| Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69:177-186 pubmed publisher |
- western blot; human; 1:500-1:2000; loading ...; fig s2e
| Wall C, Rose C, Adrian M, Zeng Y, Kirkpatrick D, Bingol B. PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin. Cell Rep. 2019;29:3280-3292.e7 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 6c, 6f, s15b
| Ghezzi C, Wong A, Chen B, Ribalet B, Damoiseaux R, Clark P. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Nat Commun. 2019;10:5444 pubmed publisher |
- western blot; rat; loading ...; fig 1a
| Brosig A, Fuchs J, Ipek F, Kroon C, Schrötter S, Vadhvani M, et al. The Axonal Membrane Protein PRG2 Inhibits PTEN and Directs Growth to Branches. Cell Rep. 2019;29:2028-2040.e8 pubmed publisher |
- western blot; human; loading ...; fig 4m
| Lu Q, Liu T, Feng H, Yang R, Zhao X, Chen W, et al. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Mol Cancer. 2019;18:111 pubmed publisher |
- immunoprecipitation; human; 1:500; loading ...; fig s2g
- western blot; human; loading ...; fig s2g
| Lee Y, Chen M, Lee J, Zhang J, Lin S, Fu T, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364: pubmed publisher |
- mass cytometry; human; loading ...; fig 3a
| Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; loading ...; fig 5d
| Zhu M, Lu T, Jia Y, Luo X, Gopal P, Li L, et al. Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. Cell. 2019;177:608-621.e12 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 4a
| Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q, et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019;129:759-773 pubmed publisher |
- western blot; human; loading ...; fig 5a
| Kim C, Hu B, Jadhav R, Jin J, Zhang H, Cavanagh M, et al. Activation of miR-21-Regulated Pathways in Immune Aging Selects against Signatures Characteristic of Memory T Cells. Cell Rep. 2018;25:2148-2162.e5 pubmed publisher |
- western blot; human; loading ...; fig 4c
| Vu L, Pickering B, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369-1376 pubmed publisher |
- western blot; mouse; loading ...; fig 4a, 4b
- western blot; human; loading ...; fig 4b
| Comiskey D, Jacob A, Sanford B, Montes M, Goodwin A, Steiner H, et al. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene. 2018;37:95-106 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 3c
| Simond A, Rao T, Zuo D, Zhao J, Muller W. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene. 2017;36:6059-6066 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 3a
| Ahmed S, Macara I. The Par3 polarity protein is an exocyst receptor essential for mammary cell survival. Nat Commun. 2017;8:14867 pubmed publisher |
- western blot; human; loading ...; fig 4a
| Gupta A, Anjomani Virmouni S, Koundouros N, Dimitriadi M, Choo Wing R, Valle A, et al. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell. 2017;65:999-1013.e7 pubmed publisher |
- western blot; mouse; 1:500; loading ...; fig 4d
| Cen M, Hu P, Cai Z, Fang T, Zhang J, Lu M. TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway. Int J Mol Med. 2017;39:569-578 pubmed publisher |
- immunocytochemistry; rat; 1:500; loading ...; fig 2c
| Callif B, Maunze B, Krueger N, Simpson M, Blackmore M. The application of CRISPR technology to high content screening in primary neurons. Mol Cell Neurosci. 2017;80:170-179 pubmed publisher |
- western blot; human; fig 1d
| Wilkerson P, Dedes K, Samartzis E, Dedes I, Lambros M, Natrajan R, et al. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget. 2017;8:6057-6066 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 1
| Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche Clary A, et al. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Oncotarget. 2017;8:7878-7890 pubmed publisher |
- western blot; human; loading ...; fig 7A
| Vuono E, Mukherjee A, Vierra D, Adroved M, Hodson C, Deans A, et al. The PTEN phosphatase functions cooperatively with the Fanconi anemia proteins in DNA crosslink repair. Sci Rep. 2016;6:36439 pubmed publisher |
- western blot; mouse; loading ...; fig 1e
| Sheen M, Marotti J, Allegrezza M, Rutkowski M, Conejo Garcia J, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5:e267 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3a
| Hau A, Leivo M, Gilder A, Hu J, Gonias S, Hansel D. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer. Cell Signal. 2017;29:96-106 pubmed publisher |
- western blot; human; 1:2000; fig 5
| Bourgonje A, Verrijp K, Schepens J, Navis A, Piepers J, Palmen C, et al. Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathol Commun. 2016;4:96 pubmed publisher |
- western blot; mouse; 1:1000; fig 3
| Lai M, Gonzalez Martin A, Cooper A, Oda H, Jin H, Shepherd J, et al. Regulation of B-cell development and tolerance by different members of the miR-17∼92 family microRNAs. Nat Commun. 2016;7:12207 pubmed publisher |
- immunohistochemistry; human; fig 1a
| Hatem R, El Botty R, Chateau Joubert S, Servely J, Labiod D, de Plater L, et al. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget. 2016;7:48206-48219 pubmed publisher |
- western blot; human; fig 3
| Tzani I, Ivanov I, Andreev D, Dmitriev R, Dean K, Baranov P, et al. Systematic analysis of the PTEN 5' leader identifies a major AUU initiated proteoform. Open Biol. 2016;6: pubmed publisher |
- western blot; human; fig s3
- immunoprecipitation; mouse; fig 2
- western blot; mouse; fig 1
| van Ree J, Nam H, Jeganathan K, Kanakkanthara A, van Deursen J. Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat Cell Biol. 2016;18:814-21 pubmed publisher |
- western blot; human; 1:1000; fig s1
| Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, et al. mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nat Commun. 2016;7:11127 pubmed publisher |
- immunohistochemistry - paraffin section; human; tbl 1
- western blot; human; fig 1
| Castillo Martin M, Thin T, Collazo Lorduy A, Cordon Cardo C. Immunopathologic Assessment of PTEN Expression. Methods Mol Biol. 2016;1388:23-37 pubmed publisher |
- western blot; human; loading ...; fig 4
| Lynch J, McEwen R, Crafter C, McDermott U, Garnett M, Barry S, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128-39 pubmed publisher |
- western blot; human; 1:1000; fig 7
| Joo M, Park J, Yoo H, Lee B, Chun H, Lee S, et al. The roles of HOXB7 in promoting migration, invasion, and anti-apoptosis in gastric cancer. J Gastroenterol Hepatol. 2016;31:1717-1726 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; fig s1
| Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher |
- western blot; human; fig 6
| Jin H, Gonzalez Martin A, Miletic A, Lai M, Knight S, Sabouri Ghomi M, et al. Transfection of microRNA Mimics Should Be Used with Caution. Front Genet. 2015;6:340 pubmed publisher |
- chromatin immunoprecipitation; human; fig 1
| Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun. 2015;6:10068 pubmed publisher |
- immunoprecipitation; human; 1:50; fig 2c
| Conde Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, et al. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity. Nat Commun. 2015;6:8093 pubmed publisher |
- western blot; human; 1:1000; fig 1c
| Lee M, Jeong M, Lee H, Han H, Ko A, Hewitt S, et al. PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat Commun. 2015;6:7769 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:100; fig 1
| Lokody I, Francis J, Gardiner J, Erler J, Swain A. Pten Regulates Epithelial Cytodifferentiation during Prostate Development. PLoS ONE. 2015;10:e0129470 pubmed publisher |
- western blot; human; fig 3
| Dorr C, Janik C, Weg M, Been R, Bader J, Kang R, et al. Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor. Mol Cancer Res. 2015;13:1238-47 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; fig 1
| Ruscetti M, Quach B, Dadashian E, Mulholland D, Wu H. Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis. Cancer Res. 2015;75:2749-59 pubmed publisher |
- western blot; human; fig 3
| Liu H, Du L, Wang R, Wei C, Liu B, Zhu L, et al. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy. Oncotarget. 2015;6:11477-91 pubmed |
- western blot; mouse; 1:1000; fig 5
| Apostoli A, Roche J, Schneider M, SenGupta S, Di Lena M, Rubino R, et al. Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression. Mol Cancer. 2015;14:85 pubmed publisher |
- western blot; mouse; 1:1000; fig s1
| Chen S, Sanjana N, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246-60 pubmed publisher |
- immunocytochemistry; human; 1:200; fig 2
- western blot; human; fig 2
| Ho J, Bassi C, Stambolic V. Characterization of nuclear PTEN and its post translational modifications. Methods. 2015;77-78:104-11 pubmed publisher |
- western blot; mouse; fig s7
| Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol. 2015;16:178-87 pubmed publisher |
- immunohistochemistry; human; tbl 2
| Eritja N, Santacana M, Maiques O, González Tallada X, Dolcet X, Matias Guiu X. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. Methods. 2015;77-78:31-40 pubmed publisher |
- immunoprecipitation; human; fig 3
- western blot; human; fig 1
| Choi M, Nakamura T, Cho S, Han X, Holland E, Qu J, et al. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson's disease models. J Neurosci. 2014;34:15123-31 pubmed publisher |
- immunoprecipitation; human
- immunocytochemistry; human; 1:200; fig 2
- western blot; human; fig 2
| Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, et al. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun. 2014;5:3393 pubmed publisher |
- western blot; mouse; 1:1000; fig 6
| Apostoli A, Skelhorne Gross G, Rubino R, Peterson N, Di Lena M, Schneider M, et al. Loss of PPAR? expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer. 2014;134:1055-66 pubmed publisher |
- western blot; human; fig 1
| Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73:2795-805 pubmed publisher |
- immunohistochemistry; mouse; 1:500
| Sha W, Thompson K, South J, Baron M, Leask A. Loss of PPAR? expression by fibroblasts enhances dermal wound closure. Fibrogenesis Tissue Repair. 2012;5:5 pubmed publisher |
| Friesen L, Gu B, Kim C. A ligand-independent fast function of RARα promotes exit from metabolic quiescence upon T cell activation and controls T cell differentiation. Mucosal Immunol. 2020;: pubmed publisher |
| Katsuyama T, Li H, Comte D, Tsokos G, Moulton V. Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. J Clin Invest. 2019;129:5411-5423 pubmed publisher |
| Perez E, de Haas S, Eiermann W, Barrios C, Toi M, Im Y, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019;19:517 pubmed publisher |
| Islam M, Xu Y, Tao W, Ubellacker J, Lim M, Aum D, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018;2:850-864 pubmed publisher |
| Gao Z, Zhang P, Xie M, Gao H, Yin L, Liu R. miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion. Cancer Cell Int. 2018;18:184 pubmed publisher |
| Saintigny P, Mitani Y, Pytynia K, Ferrarotto R, Roberts D, Weber R, et al. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018;124:3693-3705 pubmed publisher |
| Schoffski P, Cresta S, Mayer I, Wildiers H, Damian S, Gendreau S, et al. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res. 2018;20:109 pubmed publisher |
| Wang L, Cho Y, Tang Y, Wang J, Park J, Wu Y, et al. PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy. Cell Res. 2018;28:787-802 pubmed publisher |
| Oldrini B, Curiel García A, Marques C, Matia V, Uluçkan O, Graña Castro O, et al. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun. 2018;9:1466 pubmed publisher |
| Pishvaian M, Slack R, Jiang W, He A, Hwang J, Hankin A, et al. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 2018;124:2337-2346 pubmed publisher |
| Pezo R, Chen T, Berman H, Mulligan A, Razak A, Siu L, et al. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Res Treat. 2018;168:159-168 pubmed publisher |
| Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer. 2017;117:367-375 pubmed publisher |
| Kim S, Lee J, Park S, Park J, Park Y, Kang W, et al. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017;17:211 pubmed publisher |
| Yu E, Hooker E, Johnson D, Kwak M, Zou K, Luong R, et al. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis. PLoS ONE. 2017;12:e0174357 pubmed publisher |
| Yang J, Schiapparelli P, Nguyen H, Igarashi A, Zhang Q, Abbadi S, et al. Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene. 2017;36:3673-3685 pubmed publisher |
| Pomeroy E, Lee L, Lee R, Schirm D, Temiz N, Ma J, et al. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene. 2017;36:3263-3273 pubmed publisher |
| Yeom C, Zeng L, Goto Y, Morinibu A, Zhu Y, Shinomiya K, et al. LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget. 2016;7:65837-65848 pubmed publisher |
| Xiong S, Cheng J, Klausen C, Zhao J, Leung P. TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways. Oncotarget. 2016;7:61262-61272 pubmed publisher |
| Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, et al. Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Cancer Sci. 2016;107:1465-1470 pubmed publisher |
| Ágoston E, Micsik T, Acs B, Fekete K, Hahn O, Baranyai Z, et al. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. Diagn Pathol. 2016;11:61 pubmed publisher |
| Kabir T, Leigh R, Tasena H, Mellone M, Coletta R, Parkinson E, et al. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts. Aging (Albany NY). 2016;8:1608-35 pubmed publisher |
| Ahmad I, Mui E, Galbraith L, Patel R, Tan E, Salji M, et al. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proc Natl Acad Sci U S A. 2016;113:8290-5 pubmed publisher |
| Manchado E, Weissmueller S, Morris J, Chen C, Wullenkord R, Lujambio A, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534:647-51 pubmed |
| Amir S, Simion C, Umeh Garcia M, Krig S, Moss T, Carraway K, et al. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer. Br J Cancer. 2016;114:1125-34 pubmed publisher |
| Ma M, He M, Jiang Q, Yan Y, Guan S, Zhang J, et al. MiR-487a Promotes TGF-?1-induced EMT, the Migration and Invasion of Breast Cancer Cells by Directly Targeting MAGI2. Int J Biol Sci. 2016;12:397-408 pubmed publisher |
| Zhang X, Guo W, Wang X, Liu X, Huang M, Gan L, et al. Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. Oncotarget. 2016;7:22733-45 pubmed publisher |
| Phelps M, Coss C, Wang H, Cook M. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. elife. 2016;5: pubmed publisher |
| Zhou Y, Yang Q, Xu H, Zhang J, Deng H, Gao H, et al. miRNA-221-3p Enhances the Secretion of Interleukin-4 in Mast Cells through the Phosphatase and Tensin Homolog/p38/Nuclear Factor-kappaB Pathway. PLoS ONE. 2016;11:e0148821 pubmed publisher |
| Grego Bessa J, Bloomekatz J, Castel P, Omelchenko T, Baselga J, Anderson K. The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. elife. 2016;5:e12034 pubmed publisher |
| Zhang H, Yan X. Cantharidin modulates the E2F1/MCM7-miR-106b-93/p21-PTEN signaling axis in MCF-7 breast cancer cells. Oncol Lett. 2015;10:2849-2855 pubmed |
| Katsura Y, Kubota H, Kunida K, Kanno A, Kuroda S, Ozawa T. An optogenetic system for interrogating the temporal dynamics of Akt. Sci Rep. 2015;5:14589 pubmed publisher |
| Shen S, Guo M, Xiong Z, Yu Y, Zhao X, Zhang F, et al. AIF inhibits tumor metastasis by protecting PTEN from oxidation. EMBO Rep. 2015;16:1563-80 pubmed publisher |
| Lu J, Pan Y, Xia X, Gu Y, Lei Y. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma. Biomed Res Int. 2015;2015:417210 pubmed publisher |
| Cowley D, Pandya K, Khan I, Kerwin J, Owen K, Griner E. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. elife. 2015;4: pubmed publisher |
| Stamatkin C, Ratermann K, Overley C, Black E. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther. 2015;16:1341-52 pubmed publisher |
| Wang D, Mou H, Li S, Li Y, Hough S, Tran K, et al. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther. 2015;26:432-42 pubmed publisher |
| Liu Z, Ren Y, Pangas S, Adams J, Zhou W, Castrillon D, et al. FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development. Mol Endocrinol. 2015;29:1006-24 pubmed publisher |
| Hawse W, Sheehan R, Miskov Zivanov N, Menk A, Kane L, Faeder J, et al. Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions. J Immunol. 2015;194:4615-9 pubmed publisher |
| Ugalde Olano A, Egia A, Fernández Ruiz S, Loizaga Iriarte A, Zuñiga GarcÃa P, Garcia S, et al. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods. 2015;77-78:25-30 pubmed publisher |
| Niemeyer B, Parrish J, Spoelstra N, Joyal T, Richer J, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. PLoS ONE. 2015;10:e0116895 pubmed publisher |
| Kuhla A, Thrum M, Schaeper U, Fehring V, Schulze Topphoff U, Abshagen K, et al. Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. Apoptosis. 2015;20:500-11 pubmed publisher |
| Munkley J, Lafferty N, Kalna G, Robson C, Leung H, Rajan P, et al. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer. 2015;15:9 pubmed publisher |
| Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67:795-802 pubmed publisher |
| Juric D, Castel P, Griffith M, Griffith O, Won H, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2015;518:240-4 pubmed publisher |
| Rubattu S, Marchitti S, Bianchi F, Di Castro S, Stanzione R, Cotugno M, et al. The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells. PLoS ONE. 2014;9:e113108 pubmed publisher |
| Sanchez Rivera F, Papagiannakopoulos T, Romero R, Tammela T, Bauer M, Bhutkar A, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516:428-31 pubmed publisher |
| Fu X, Creighton C, Biswal N, Kumar V, Shea M, Herrera S, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014;16:430 pubmed publisher |
| Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi N, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380-4 pubmed publisher |
| Yahiaoui O, Nunes J, Castanier C, Devillier R, Broussais F, Fabre A, et al. Constitutive AKT activation in follicular lymphoma. BMC Cancer. 2014;14:565 pubmed publisher |
| Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, et al. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A?? via AKT in prostate cancer cells. Oncotarget. 2014;5:6289-99 pubmed publisher |
| Patel M, Gomez N, McFadden A, Moats Staats B, Wu S, Rojas A, et al. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition. Mol Cancer Res. 2014;12:1610-20 pubmed publisher |
| Chiang E, Tsai S, Kuo Y, Pai M, Chiu H, Rodriguez R, et al. Caffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/Akt and AMPK signaling pathways. PLoS ONE. 2014;9:e99631 pubmed publisher |
| Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J, et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature. 2014;510:402-6 pubmed publisher |
| Andre F, O Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580-91 pubmed publisher |
| Miller K, Dieras V, Harbeck N, Andre F, Mahtani R, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32:1437-44 pubmed publisher |
| Nho R, Hergert P. IPF fibroblasts are desensitized to type I collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS ONE. 2014;9:e94616 pubmed publisher |
| Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo O, et al. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS ONE. 2014;9:e94132 pubmed publisher |
| Heller B, Ghidinelli M, Voelkl J, Einheber S, Smith R, Grund E, et al. Functionally distinct PI 3-kinase pathways regulate myelination in the peripheral nervous system. J Cell Biol. 2014;204:1219-36 pubmed publisher |
| Miyasaka A, Oda K, Ikeda Y, Wada Hiraike O, Kashiyama T, Enomoto A, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14:179 pubmed publisher |
| Bourgon R, Lu S, Yan Y, Lackner M, Wang W, Weigman V, et al. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res. 2014;20:2080-91 pubmed publisher |
| Chen C, Lei W, Chen W, Zhong J, Gao X, Li B, et al. Serum TGF-?1 and SMAD3 levels are closely associated with coronary artery disease. BMC Cardiovasc Disord. 2014;14:18 pubmed publisher |
| Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS ONE. 2014;9:e88291 pubmed publisher |
| Stjernström A, Karlsson C, Fernandez O, Söderkvist P, Karlsson M, Thunell L. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 2014;3:337-48 pubmed publisher |
| Wong C, Martincorena I, Rust A, Rashid M, Alifrangis C, Alexandrov L, et al. Inactivating CUX1 mutations promote tumorigenesis. Nat Genet. 2014;46:33-8 pubmed publisher |
| Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston R, et al. Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014;20:595-603 pubmed publisher |
| Karapetis C, Jonker D, Daneshmand M, Hanson J, O Callaghan C, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744-53 pubmed publisher |
| Atreya C, Sangale Z, Xu N, Matli M, Tikishvili E, Welbourn W, et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013;2:496-506 pubmed publisher |
| Garcia Carracedo D, Turk A, Fine S, Akhavan N, Tweel B, Parsons R, et al. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2013;19:6830-41 pubmed publisher |
| Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer. 2013;109:2714-23 pubmed publisher |
| Beckham T, Cheng J, Lu P, Marrison S, Norris J, Liu X. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS ONE. 2013;8:e76593 pubmed publisher |
| Yoshikawa T, Otsuka M, Kishikawa T, Takata A, Ohno M, Shibata C, et al. Unique haploinsufficient role of the microRNA-processing molecule Dicer1 in a murine colitis-associated tumorigenesis model. PLoS ONE. 2013;8:e71969 pubmed publisher |
| Yip W, Choo C, Leong V, Leong P, Jabar M, Seow H. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS. 2013;121:954-66 pubmed publisher |
| Hsu H, Cheng L, Ho T, Kuo W, Lin Y, Chen M, et al. Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour Biol. 2014;35:303-13 pubmed publisher |
| Locke F, Zha Y, Zheng Y, Driessens G, Gajewski T. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013;191:1677-85 pubmed publisher |
| Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. Int J Oncol. 2013;43:919-26 pubmed publisher |
| Chang K, Tsai S, Chen S, Tsou H, Yen C, Liu K, et al. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J Biomed Sci. 2013;20:43 pubmed publisher |
| Waniczek D, Snietura M, Pigłowski W, Rdes J, Kopec A, Młynarczyk Liszka J, et al. Analysis of PTEN expression in large intestine polyps and its relation to the recognized histopathological and clinical risk factors for cancer development in this location. Contemp Oncol (Pozn). 2012;16:310-5 pubmed publisher |
| Sharma P, Knowell A, Chinaranagari S, Komaragiri S, Nagappan P, Patel D, et al. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN. Mol Cancer. 2013;12:67 pubmed publisher |
| Beckham T, Cheng J, Lu P, Shao Y, Troyer D, Lance R, et al. Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling. Oncogenesis. 2013;2:e49 pubmed publisher |
| Yin L, Cai W, Liu C, Chen Y, Hu J, Jiang J, et al. Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry. PLoS ONE. 2013;8:e62971 pubmed publisher |
| Burgers T, Hoffmann M, Collins C, Zahatnansky J, Alvarado M, Morris M, et al. Mice lacking pten in osteoblasts have improved intramembranous and late endochondral fracture healing. PLoS ONE. 2013;8:e63857 pubmed publisher |
| Tinker A, Ellard S, Welch S, Moens F, Allo G, Tsao M, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130:269-74 pubmed publisher |
| Singh M, Chaudhry P, Fabi F, Asselin E. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer. 2013;13:233 pubmed publisher |
| Waniczek D, Snietura M, Młynarczyk Liszka J, Pigłowski W, Kopec A, Lange D, et al. PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol. 2013;64:15-20 pubmed |
| Sarfstein R, Friedman Y, Attias Geva Z, Fishman A, Bruchim I, Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS ONE. 2013;8:e61537 pubmed publisher |
| Sampurno S, Bijenhof A, Cheasley D, Xu H, Robine S, Hilton D, et al. The Myb-p300-CREB axis modulates intestine homeostasis, radiosensitivity and tumorigenesis. Cell Death Dis. 2013;4:e605 pubmed publisher |
| Ludyga N, Englert S, Pflieger K, Rauser S, Braselmann H, Walch A, et al. The impact of cysteine-rich intestinal protein 1 (CRIP1) in human breast cancer. Mol Cancer. 2013;12:28 pubmed publisher |
| Dufour J, Pommier A, Alves G, de Boussac H, Lours Calet C, Volle D, et al. Lack of liver X receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell. PLoS ONE. 2013;8:e58876 pubmed publisher |
| Muppala S, Mudduluru G, Leupold J, Buergy D, Sleeman J, Allgayer H. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS ONE. 2013;8:e59563 pubmed publisher |
| Wu R, Baker S, Hu T, Norman K, Fearon E, Cho K. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol. 2013;182:1391-9 pubmed publisher |
| Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman K, et al. Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med. 2013;5:57-64 pubmed |
| Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta Huspenina J, et al. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol. 2013;44:829-36 pubmed publisher |
| Rodriguez S, Huynh Do U. Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor. FASEB J. 2013;27:632-44 pubmed publisher |
| Helmy K, Halliday J, Fomchenko E, Setty M, Pitter K, Hafemeister C, et al. Identification of global alteration of translational regulation in glioma in vivo. PLoS ONE. 2012;7:e46965 pubmed publisher |
| Kayali S, Giraud G, Morle F, Guyot B. Spi-1, Fli-1 and Fli-3 (miR-17-92) oncogenes contribute to a single oncogenic network controlling cell proliferation in friend erythroleukemia. PLoS ONE. 2012;7:e46799 pubmed publisher |
| Teng Y, Manavalan T, Hu C, Medjakovic S, Jungbauer A, Klinge C. Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells. Toxicol Sci. 2013;131:71-83 pubmed publisher |
| Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 2012;7:1513-21 pubmed |
| Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman K, et al. Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int J Mol Sci. 2012;13:9980-91 pubmed publisher |
| Iqbal J, Thike A, Cheok P, Tse G, Tan P. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology. 2012;61:652-9 pubmed publisher |
| Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, DU Four S, et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol. 2012;41:1029-35 pubmed publisher |
| Barbareschi M, Cuorvo L, Girlando S, Bragantini E, Eccher C, Leonardi E, et al. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch. 2012;461:129-39 pubmed publisher |
| Snietura M, Jaworska M, Mlynarczyk Liszka J, Goraj Zając A, Piglowski W, Lange D, et al. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS ONE. 2012;7:e33396 pubmed publisher |
| Cantrup R, Dixit R, Palmesino E, Bonfield S, Shaker T, Tachibana N, et al. Cell-type specific roles for PTEN in establishing a functional retinal architecture. PLoS ONE. 2012;7:e32795 pubmed publisher |
| Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, et al. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS ONE. 2012;7:e30427 pubmed publisher |
| Lerch J, Kuo F, Motti D, Morris R, Bixby J, Lemmon V. Isoform diversity and regulation in peripheral and central neurons revealed through RNA-Seq. PLoS ONE. 2012;7:e30417 pubmed publisher |
| Heindl M, Händel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 2012;142:1093-1096.e6 pubmed publisher |
| Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106:719-26 pubmed publisher |
| Valkov A, Kilvaer T, Sorbye S, Donnem T, Smeland E, Bremnes R, et al. The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med. 2011;9:200 pubmed publisher |
| Kye M, Neveu P, Lee Y, Zhou M, Steen J, Sahin M, et al. NMDA mediated contextual conditioning changes miRNA expression. PLoS ONE. 2011;6:e24682 pubmed publisher |
| Lee D, Do I, Choi K, Sung C, Jang K, Choi D, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25:131-9 pubmed publisher |
| Ahmad I, Patel R, Liu Y, Singh L, Taketo M, Wu X, et al. Ras mutation cooperates with ?-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2011;2:e124 pubmed publisher |
| Pitter K, Galban C, Galban S, Tehrani O, Saeed Tehrani O, Li F, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE. 2011;6:e14545 pubmed publisher |
| Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol. 2011;19:173-83 pubmed publisher |
| Van Themsche C, Chaudhry P, Leblanc V, Parent S, Asselin E. XIAP gene expression and function is regulated by autocrine and paracrine TGF-beta signaling. Mol Cancer. 2010;9:216 pubmed publisher |
| Javle M, Shroff R, Xiong H, Varadhachary G, Fogelman D, Reddy S, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368 pubmed publisher |
| Castellino R, Barwick B, Schniederjan M, Buss M, Becher O, Hambardzumyan D, et al. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS ONE. 2010;5:e10849 pubmed publisher |
| Kim T, Franco H, Jung S, Qin J, Broaddus R, Lydon J, et al. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene. 2010;29:3770-80 pubmed publisher |
| Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 2009;101:1676-82 pubmed publisher |
| McBride S, Perez D, Polley M, VandenBerg S, Smith J, Zheng S, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97:33-40 pubmed publisher |
| Guertin D, Stevens D, Saitoh M, Kinkel S, Crosby K, Sheen J, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell. 2009;15:148-59 pubmed publisher |
| Zheng H, Ying H, Yan H, Kimmelman A, Hiller D, Chen A, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129-33 pubmed publisher |
| Laguë M, Paquet M, Fan H, Kaartinen M, Chu S, Jamin S, et al. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis. 2008;29:2062-72 pubmed publisher |
| Saal L, Gruvberger Saal S, Persson C, Lövgren K, Jumppanen M, Staaf J, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. 2008;40:102-7 pubmed |
